Oct 29, 2025 07:00AM
Oct 29, 2025 06:00AM
Oct 29, 2025 06:00AM
Oct 29, 2025 03:53AM
Oct 27, 2025 07:00AM
Oct 27, 2025 07:00AM
Oct 23, 2025 06:03AM NLS Pharmaceutics and Kadimastem receive Nasdaq approval for merger
Oct 23, 2025 06:01AM
Sep 30, 2025 07:01AM
Sep 30, 2025 07:00AM
Sep 10, 2025 06:00AM
Sep 4, 2025 07:39AM
Sep 4, 2025 07:38AM
Jul 17, 2025 07:00AM NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type
Jul 17, 2025 07:00AM
Jun 30, 2025 07:00AM
Jun 16, 2025 07:00AM
Apr 15, 2025 09:00AM
Mar 10, 2025 07:04AM
Mar 10, 2025 07:00AM
Feb 25, 2025 09:05AM Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Feb 10, 2025 07:30AM
Jan 31, 2025 07:30AM
Jan 28, 2025 07:32AM
Jan 28, 2025 07:30AM
Jan 16, 2025 09:32AM
Jan 8, 2025 07:42AM
Dec 30, 2024 07:30AM NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

1,155,356 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All